S&P Futures
6,012.25 +5.75 (+0.10%) Dow Futures
44,860.00 +34.00 (+0.08%) Nasdaq Futures
20,901.00 +20.75 (+0.10%) Russell 2000 Futures
2,444.20 -6.80 (-0.28%) Crude Oil
69.55 +0.61 (+0.88%) Gold
2,630.70 +12.20 (+0.47%)
CytoMed Therapeutics Limited (GDTC)
| Previous Close | 2.2600 |
| Open | 2.0672 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.9500 - 2.2000 |
| 52 Week Range | 1.2000 - 5.5000 |
| Volume | |
| Avg. Volume | 12,463 |
| Market Cap | 25.388M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
GlobeNewswireUpdate on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT0
Simply Wall St.Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength...
